60 Degrees Pharmaceuticals reported earnings of per SXTP share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.61 |
| Last Year's EPS | -$ 4.33 |
| EPS YoY Change |
Out of the last 23 earnings reporting periods, 60 Degrees Pharmaceuticals beat analysts’ expectations 3 times and fell short of expectations 13 time(s). 60 Degrees Pharmaceuticals reported earnings per share of in the last report surpassing an estimated EPS of -$ 0.61 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.61 | -$ 1.25 | - | |
| Aug 14, 2026 | -$ 0.74 | -$ 0.90 | -$ 5.00 | |
| May 15, 2026 | -$ 0.76 | -$ 1.28 | -$ 6.24 | |
| Mar 26, 2026 | -$ 2.28 | -$ 1.69 | -$ 9.18 | |
| Nov 13, 2025 | -$ 1.84 | -$ 2.64 | -$ 14.20 | |
| Aug 13, 2025 | -$ 1.24 | -$ 1.25 | -$ 18.60 | |
| Aug 12, 2025 | -$ 4.96 | -$ 5.00 | -$ 0.85 | |
| May 15, 2025 | -$ 5.24 | -$ 6.24 | $ 7.20 | |
| Apr 7, 2025 | -$ 4.77 | -$ 9.18 | -$ 1.06 | |
| Mar 27, 2025 | -$ 4.01 | -$ 14.20 | -$ 0.72 | |
| Nov 14, 2024 | -$ 12.00 | -$ 18.60 | -$ 0.66 | |
| Aug 14, 2024 | -$ 0.79 | -$ 0.85 | -$ 1.88 | |
| May 15, 2024 | -$ 38.42 | $ 7.20 | -$ 1.87 | |
| Apr 1, 2024 | -$ 0.65 | -$ 1.06 | -$ 1.20 | |
| Nov 20, 2023 | -$ 0.62 | -$ 0.72 | -$ 1.04 | |
| Aug 25, 2023 | $ 0.174 | -$ 0.66 | -$ 1.54 | |
| Jun 8, 2023 | - | -$ 1.88 | -$ 37.68 | |
| Mar 31, 2023 | - | -$ 1.87 | -$ 0.94 | |
| Dec 31, 2022 | - | -$ 1.20 | - | - |
| Sep 30, 2022 | - | -$ 1.04 | - | - |
60 Degrees Pharmaceuticals’s stock was trading at $ 0.52 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, SXTP’s price decreased to $ 0.5179 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | | $ 0.52 | $ 0.5179 | |
| Aug 14, 2026 | -$ 0.90 | $ 1.18 | $ 1.08 | |
| May 15, 2026 | -$ 1.28 | $ 1.46 | $ 1.44 | |
| Mar 26, 2026 | -$ 1.69 | $ 1.55 | $ 1.50 | |
| Nov 13, 2025 | -$ 2.64 | $ 4.92 | $ 3.64 | |
| Aug 13, 2025 | -$ 1.25 | $ 5.40 | $ 5.24 | |
| Aug 12, 2025 | -$ 5.00 | $ 5.52 | $ 5.40 | |
| May 15, 2025 | -$ 6.24 | $ 9.00 | $ 9.88 | |
| Apr 7, 2025 | -$ 9.18 | $ 7.08 | $ 11.48 | |
| Mar 27, 2025 | -$ 14.20 | $ 7.52 | $ 7.36 | |
| Nov 14, 2024 | -$ 18.60 | $ 19.60 | $ 17.96 | |
| Aug 14, 2024 | -$ 0.85 | $ 27.00 | $ 33.00 | |
| May 15, 2024 | $ 7.20 | $ 52.80 | $ 53.52 | |
| Apr 1, 2024 | -$ 1.06 | $ 62.64 | $ 67.60 | |
| Nov 20, 2023 | -$ 0.72 | $ 166.84 | $ 147.52 | |
| Aug 25, 2023 | -$ 0.66 | $ 364.80 | $ 331.20 |
60 Degrees Pharmaceuticals released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
60 Degrees Pharmaceuticals beat analysts’ expectations during the last earnings period by
